3 mL Inhaled Methoxyflurane for Intrauterine Device (IUD) Insertion

Methoxyflurane is a short-acting, self-administered inhaled analgesic that has demonstrated rapid and effective pain relief in acute trauma, emergency, and procedural settings. It is non-narcotic, allows patients to control dosing, and does not require intravenous access or prolonged recovery, making it suitable for short outpatient procedures. Existing studies indicate that Methoxyflurane provides faster onset of pain relief compared to standard analgesics, is generally well-tolerated, and has only transient, non-serious adverse effects such as dizziness or headache.

This study aims to evaluate the efficacy of 3 mL of inhaled Methoxyflurane, delivered via Penthrox inhaler, in reducing pain and anxiety during IUD insertion. The primary objective is to assess patient satisfaction with pain management. Secondary outcomes include procedural pain scores, anxiety levels, and the incidence of adverse events. This trial seeks to provide evidence for an effective, safe, and patient-centered approach to pain management during IUD insertion, potentially improving patient experience and access to long-acting contraceptive options.

Inclusion criteria

• Patients with a uterus.
• Ages 18 to 55 years.
• Undergoing any intrauterine device (IUD) insertion.
• English-speaking participants.
• Ability to use an inhaler device.
• Willing to receive a cervical block for their IUD insertion

Exclusion criteria

• Inability to provide informed consent.
• Confirmed pregnancy.
• Use of pain medication other than NSAIDs or acetaminophen (e.g., opioids, benzodiazepines, muscle relaxants) within 24 hours prior to the intervention.
• Use of cannabis within 24 hours prior to the intervention.
• Administration of misoprostol within 24 hours prior to the intervention.
• Altered level of consciousness due to any cause, including head injury, drugs, or alcohol.
• History of severe adverse reactions to Penthrox (methoxyflurane) or other halogenated anesthetic agents, or to any ingredient in the formulation (including non-medicinal ingredients or container components).
• Anatomical variance, such as distorted uterine cavity, bicornuate uterus, uterus didelphys, or cervical stenosis.
• Clinically significant renal and/or liver impairment.
• Known or genetic susceptibility to malignant hyperthermia.
• Clinically evident hemodynamic or cardiovascular instability, or respiratory depression.
• Not NPO according to hospital guidelines.